Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs Ribociclib (Primary)
- Indications Adrenal cancer; Advanced breast cancer; Bladder cancer; Haematological malignancies; Head and neck cancer; Mesothelioma; Penile cancer; Sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer
- Focus Therapeutic Use
- Acronyms SIGNATURE
- Sponsors Novartis Pharmaceuticals
- 10 Jun 2018 Status changed from active, no longer recruiting to completed.
- 22 Sep 2017 Planned End Date changed from 15 Apr 2018 to 31 Oct 2017.
- 22 Sep 2017 Planned primary completion date changed from 15 Apr 2018 to 31 Oct 2017.